Neratinib plus capecitabine for HER2-negative breast cancer brain mets
Part of Brain & nervous system, Cancer, Skin clinical trials.
This study tests whether neratinib plus capecitabine can slow or shrink breast cancer that has spread to the brain. It is for people whose cancer shows an “overactive HER2 signal” on a specific tumor test, even though their cancer is labeled HER2-negative.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older and can have the study explained to you and sign consent
- Your breast cancer is HER2-negative on recent tumor testing, and your tumor tissue also shows an abnormally active HER2 signal on the CELsignia test
- You have one or more brain metastases on imaging (and you can get an MRI)
- You have measurable cancer outside the brain that can be biopsied for research tissue
- You can have a tumor biopsy and you’re medically well enough for it (no recent major surgery; recent timing limits for chemo/radiation/investigational drugs)
- Your heart function is good enough (baseline ejection fraction at least 50%), and your overall status is fair (ECOG 0–2)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of targeted drugs for HER2-positive breast cancer that has spread to the brain. You might be able to join if you have brain metastases and are either newly diagnosed or have had prior brain radiation.
This study is testing a new targeted therapy for people with HER2-positive breast cancer that has spread to the brain. It aims to see if the drug can help shrink brain tumors and improve outcomes for two groups: those with cancer in the fluid around the brain and those without.
This trial tests two new drugs, SHR-A1811 and THPy, for women with HER2-positive advanced breast cancer that has spread to the brain. It aims to see if this combination can shrink brain tumors and improve outcomes for patients who have not yet had systemic treatment for advanced disease.
This trial studies a combination of two oral drugs, neratinib and capecitabine, for people with HER2-positive stomach, esophageal, or gastroesophageal junction cancer that has spread to the brain. The goal is to see if this treatment can shrink tumors and improve outcomes.
This trial tests a combination of two anti-cancer drugs for people with HER2-positive breast cancer that has spread to the brain and has not responded to a prior antibody-drug conjugate treatment. The goal is to see if this combination can shrink or control brain metastases.
This trial tests whether adding neratinib to T-DXd (trastuzumab deruxtecan) works better than T-DXd alone for women with HER2-positive breast cancer that has spread to the brain. It is for those who have not had these specific drugs before.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.